Skip to main content
SpringerLink
Log in

Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478

  • Paper
  • Published:
Photochemical & Photobiological Sciences Aims and scope Submit manuscript

Abstract

Photodynamic therapy (PDT) is a selective treatment modality against cancer.PDT is based on the preferential retention of photosensitizers (PSs), in the tumour and subsequent light exposure which activates the PS and generates reactive oxygen species. Multimodality therapy is increasingly relevant in cancer treatment and PDT has been shown as an effective adjuvant to other anti-cancer modalities. The present study reports on the combination of PDT and an epidermal growth factor receptor (EGFR) specific tyrosine kinase inhibitor (TKI), Tyrphostin AG1478. The combination was studied in two cell lines; A-431 and NuTu-19, expressing EGFR and sensitive to Tyrphostin treatment, but with different sensitivity towards photochemical EGFR damage. A-431 cells were treated with the PS meso-tetraphenylporphine with 2 sulfonate groups on adjacent phenyl rings (TPPS2a) in order to target mainly the endo/lysosomal compartments (18 h incubation followed by a 4 h chase in drug-free medium) or the plasma membrane (30 min incubation) upon light exposure. The EGFR was inhibited after PDT in A-431 cells only when TPPS2a was located on the plasma membrane, but both treatment regimes resulted in synergistic inhibition of cell growth when combined with Tyrphostin. TPPS2a treatment of NuTu-19 cells, designed for endo/lysosomal localization, followed by light attenuated EGFR phosphorylation but resulted in additive or antagonistic effects on cell growth when Tyrphostin was administered prior to or after PDT respectively. It was therefore concluded that photochemical damage of EGFR does not predict the treatment outcome when PDT is combined with Tyrphostin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D. E. Dolmans, D. Fukumura, R. K. Jain, Photodynamic therapy for cancer, Nat. Rev. Cancer, 2003, 3, 380–387.

    Article  CAS  PubMed  Google Scholar 

  2. T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, Q. Peng, Photodynamic therapy, J. Natl. Cancer Inst., 1998, 90, 889–905.

    Article  CAS  PubMed  Google Scholar 

  3. E. Buytaert, M. Dewaele, P. Agostinis, Molecular effectors of multiple cell death pathways initiated by photodynamic therapy, Biochim. Biophys. Acta, 2007, 1776, 86–107.

    CAS  PubMed  Google Scholar 

  4. J. Moan, K. Berg, The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen, Photochem. Photobiol., 1991, 53, 549–553.

    Article  CAS  PubMed  Google Scholar 

  5. R. J. Pacifico, K. K. Wang, L. M. Wongkeesong, N. S. Buttar, L. S. Lutzke, Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus, Clin. Gastroenterol. Hepatol., 2003, 1, 252–257.

    Article  PubMed  Google Scholar 

  6. P. Baas, L. Murrer, F. A. Zoetmulder, F. A. Stewart, H. B. Ris, Z. N. van, J. L. Peterse, E. J. Rutgers, Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies, Br. J. Cancer, 1997, 76, 819–826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. M. S. Kavuru, A. C. Mehta, I. Eliachar, Effect of photodynamic therapy and external beam radiation therapy on juvenile laryngotracheobronchial papillomatosis, Am. Rev. Respir. Dis., 1990, 141, 509–510.

    Article  CAS  PubMed  Google Scholar 

  8. D. J. Gilbert, Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy, J. Drugs Dermatol., 2005, 4, 161–163.

    PubMed  Google Scholar 

  9. M. G. del Carmen, I. Rizvi, Y. Chang, A. C. Moor, E. Oliva, M. Sherwood, B. Pogue, T. Hasan, Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo, J. Natl. Cancer Inst., 2005, 97, 1516–1524.

    Article  CAS  PubMed  Google Scholar 

  10. A. Zimmermann, H. Walt, U. Haller, P. Baas, S. D. Klein, Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient, Cancer Chemother. Pharmacol., 2003, 51, 147–154.

    Article  CAS  PubMed  Google Scholar 

  11. A. K. Sinha, S. Anand, B. J. Ortel, Y. Chang, Z. Mai, T. Hasan, E. V. Maytin, Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells, Br. J. Cancer, 2006, 95, 485–495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. V. Kirveliene, G. Grazeliene, D. Dabkeviciene, I. Micke, D. Kirvelis, B. Juodka, J. Didziapetriene, Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo, Cancer Chemother. Pharmacol., 2006, 57, 65–72.

    Article  CAS  PubMed  Google Scholar 

  13. A. Ferrario, A. M. Fisher, N. Rucker, C. J. Gomer, Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors, Cancer Res., 2005, 65, 9473–9478.

    Article  CAS  PubMed  Google Scholar 

  14. W. Liu, M. R. Baer, M. J. Bowman, P. Pera, X. Zheng, J. Morgan, R. A. Pandey, A. R. Oseroff, The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2, Clin. Cancer Res., 2007, 13, 2463–2470.

    Article  CAS  PubMed  Google Scholar 

  15. A. Ferrario, C. J. Gomer, Avastin enhances photodynamic therapy treatment of Kaposi’s sarcoma in a mouse tumor model, J. Environ. Pathol. Toxicol. Oncol., 2006, 25, 251–259.

    Article  CAS  PubMed  Google Scholar 

  16. F. Ciardiello, G. Tortora, EGFR antagonists in cancer treatment, New Engl. J. Med., 2008, 358, 1160–1174.

    Article  CAS  PubMed  Google Scholar 

  17. E. K. Rowinsky, The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors, Annu. Rev. Med., 2004, 55, 433–457.

    Article  CAS  PubMed  Google Scholar 

  18. A. Wells, EGF receptor, Int. J. Biochem. Cell Biol., 1999, 31, 637–643.

    Article  CAS  PubMed  Google Scholar 

  19. F. A. Al-Obeidi, K. S. Lam, Development of inhibitors for protein tyrosine kinases, Oncogene, 2000, 19, 5690–5701.

    Article  CAS  PubMed  Google Scholar 

  20. Y. Zhou, M. G. Brattain, Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis, Cancer Res., 2005, 65, 5848–5856.

    Article  CAS  PubMed  Google Scholar 

  21. Y. Han, C. G. Caday, A. Nanda, W. K. Cavenee, H. J. Huang, Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors, Cancer Res., 1996, 56, 3859–3861.

    CAS  PubMed  Google Scholar 

  22. W. A. Denny, Irreversible inhibitors of the erbB family of protein tyrosine kinases, Pharmacol. Ther., 2002, 93, 253–261.

    Article  CAS  PubMed  Google Scholar 

  23. A. Weyergang, P. K. Selbo, K. Berg, Photochemically stimulated drug delivery increases the cytotoxicity and specificity of EGF-saporin, J. Controlled Release, 2006, 111, 165–173.

    Article  CAS  Google Scholar 

  24. A. Weyergang, P. K. Selbo, K. Berg, Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor, Biochem. Pharmacol., 2007, 74, 226–235.

    Article  CAS  PubMed  Google Scholar 

  25. K. Berg, A. Western, J. C. Bommer, J. Moan, Intracellular localization of sulfonated meso-tetraphenylporphines in a human carcinoma cell line, Photochem. Photobiol., 1990, 52, 481–487.

    Article  CAS  PubMed  Google Scholar 

  26. R. Soffietti, R. Ruda, E. Trevisan, New chemotherapy options for the treatment of malignant gliomas, Anticancer Drugs, 2007, 18, 621–632.

    Article  CAS  PubMed  Google Scholar 

  27. M. Zhang, Z. Zhang, C. K. Goldman, J. Janik, T. A. Waldmann, Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody, Blood, 2005, 105, 1231–1236.

    Article  CAS  PubMed  Google Scholar 

  28. C. H. Yun, T. J. Boggon, Y. Li, M. S. Woo, H. Greulich, M. Meyerson, M. J. Eck, Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity, Cancer Cell, 2007, 11, 217–227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, C. S. Di, J. Tabernero, M. Guzman, S. Rodriguez, J. Arribas, J. Palacios, J. Baselga, Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting, Clin. Cancer Res., 2004, 10, 6487–6501.

    Article  CAS  PubMed  Google Scholar 

  30. H. K. Gan, F. Walker, A. W. Burgess, A. Rigopoulos, A. M. Scott, T. G. Johns, The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806, J. Biol. Chem., 2007, 282, 2840–2850.

    Article  CAS  PubMed  Google Scholar 

  31. G. Partik, K. Hochegger, M. Schorkhuber, B. Marian, Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro, J. Cancer Res. Clin. Oncol., 1999, 125, 379–388.

    Article  CAS  PubMed  Google Scholar 

  32. T. G. Johns, R. B. Luwor, C. Murone, F. Walker, J. Weinstock, A. A. Vitali, R. M. Perera, A. A. Jungbluth, E. Stockert, L. J. Old, E. C. Nice, A. W. Burgess, A. M. Scott, Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478, Proc. Natl. Acad. Sci. USA, 2003, 100, 15871–15876.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. R. Mandic, C. J. Rodgarkia-Dara, L. Zhu, B. J. Folz, M. Bette, E. Weihe, A. Neubauer, J. A. Werner, Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor, FEBS Lett., 2006, 580, 4793–4800.

    Article  CAS  PubMed  Google Scholar 

  34. A. P. Castano, N. Tatiana, M. R. Hamblin, Mechanisms in photodynamic therapy: part one - photosensitizers, photochemistry and cellular localization, Photodiagn. Photodyn. Ther., 2004, 1, 279–293.

    Article  CAS  Google Scholar 

  35. W. L. Yip, A. Weyergang, K. Berg, H. H. Tonnesen, P. K. Selbo, Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells, Mol. Pharm., 2007, 4, 241–251.

    Article  CAS  PubMed  Google Scholar 

  36. A. Bonsted, B. O. Engesaeter, A. Hogset, G. M. Maelandsmo, L. Prasmickaite, C. D’Oliveira, W. E. Hennink, J. H. van Steenis, K. Berg, Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor, J. Gene Med., 2006, 8, 286–297.

    Article  CAS  PubMed  Google Scholar 

  37. N. Ahmad, K. Kalka, H. Mukhtar, In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photodynamic therapy, Oncogene, 2001, 20, 2314–2317.

    Article  CAS  PubMed  Google Scholar 

  38. S. M. Schieke, C. von Montfort, D. P. Buchczyk, A. Timmer, S. Grether-Beck, J. Krutmann, N. J. Holbrook, L. O. Klotz, Singlet oxygen-induced attenuation of growth factor signaling: possible role of ceramides, Free Radical Res., 2004, 38, 729–737.

    Article  CAS  Google Scholar 

  39. P. de Witte, P. Agostinis, J. Van Lint, W. Merlevede, J. R. Vandenheede, Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin, Biochem. Pharmacol., 1993, 46, 1929–1936.

    Article  PubMed  Google Scholar 

  40. A. Weyergang, O. Kaalhus, K. Berg, Photodynamic therapy with an endocytically located photosensitizer cause a rapid activation of the mitogen-activated protein kinases extracellular signal-regulated kinase, p38, and c-Jun NH2 terminal kinase with opposing effects on cell survival, Mol. Cancer Ther., 2008, 7, 1740–1750, DOI: 10.1158/1535-7163.MCT-08-0020

    Article  CAS  PubMed  Google Scholar 

  41. W. Liu, A. R. Oseroff, H. Baumann, Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells, Cancer Res., 2004, 64, 6579–6587.

    Article  CAS  PubMed  Google Scholar 

  42. T. H. Yang, C. T. Chen, C. P. Wang, P. J. Lou, Photodynamic therapy suppresses the migration and invasion of head and neck cancer cells in vitro, Oral Oncol., 2007, 43, 358–365.

    Article  CAS  PubMed  Google Scholar 

  43. S. Zhuang, G. D. Ouedraogo, I. E. Kochevar, Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases, Oncogene, 2003, 22, 4413–4424.

    Article  CAS  PubMed  Google Scholar 

  44. J. L. Fischel, P. Formento, G. Milano, Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors, Br. J. Cancer, 2005, 92, 1063–1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. J. Amann, S. Kalyankrishna, P. P. Massion, J. E. Ohm, L. Girard, H. Shigematsu, M. Peyton, D. Juroske, Y. Huang, S. J. Stuart, Y. H. Kim, J. R. Pollack, K. Yanagisawa, A. Gazdar, J. D. Minna, J. M. Kurie, D. P. Carbone, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer, Cancer Res., 2005, 65, 226–235.

    CAS  PubMed  Google Scholar 

  46. A. P. Castano, P. Mroz, M. R. Hamblin, Photodynamic therapy and anti-tumour immunity, Nat. Rev. Cancer, 2006, 6, 535–545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310, Oslo, Norway

    Anette Weyergang, Olav Kaalhus & Kristian Berg

Authors
  1. Anette Weyergang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olav Kaalhus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kristian Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anette Weyergang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weyergang, A., Kaalhus, O. & Berg, K. Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478. Photochem Photobiol Sci 7, 1032–1040 (2008). https://doi.org/10.1039/b806209a

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1039/b806209a

Search

Navigation